Compare BWEN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | KZIA |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 56.8M |
| IPO Year | 2009 | 2002 |
| Metric | BWEN | KZIA |
|---|---|---|
| Price | $2.41 | $6.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 247.6K | 223.7K |
| Earning Date | 05-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $146,785,000.00 | N/A |
| Revenue This Year | $11.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.41 | $0.64 |
| 52 Week High | $4.15 | $17.40 |
| Indicator | BWEN | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 46.80 |
| Support Level | $2.29 | $4.91 |
| Resistance Level | $2.49 | $6.34 |
| Average True Range (ATR) | 0.20 | 0.56 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 25.00 | 66.69 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.